Inhibition of Glioma Angiogenesis and Growth in Vivo by Systemic Treatment with a Monoclonal Antibody against Vascular Endothelial Growth Factor Receptor-2

Philip Kunkel, Ulrike Ulbricht, Peter Bohlen, et al.

Cancer Res 2001;61:6624-6628.

Updated Version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/61/18/6624

Cited Articles
This article cites 21 articles, 9 of which you can access for free at:
http://cancerres.aacrjournals.org/content/61/18/6624.full.html#ref-list-1

Citing Articles
This article has been cited by 54 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/61/18/6624.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.
Inhibition of Glioma Angiogenesis and Growth in Vivo by Systemic Treatment with a Monoclonal Antibody against Vascular Endothelial Growth Factor Receptor-2

Philip Kunkel, Ulrike Ulbricht, Peter Bohlen, Marc A. Brockmann, Regina Fillbrandt, Dimitrios Stavrou, Manfred Westphal, Katrin Lamszus

Departments of Neurosurgery [P. K., U. U., M. A. B., R. F., M. W.] and Neuropathology [D. S., K. L.], University Hospital Hamburg-Eppendorf, 20246 Hamburg, Germany, and ImClone Systems, Inc. [P. B.], New York, New York 10014

Abstract

Using an orthotopic intracerebral model, we investigated whether systemic treatment with DC101, a monoclonal antibody against vascular endothelial growth factor receptor (VEGFR)-2, could inhibit angiogenesis and the growth of human glioblastoma cells in severe combined immunodeficient mice. Intraperitoneal treatment with DC101, control IgG, or PBS was initiated either on day 0 or, in another series, on day 6 after tumor cell implantation, and animals were killed −2 weeks after tumor cell injection. Tumor volumes in animals treated with DC101 were reduced by at least 40% compared with animals treated with control IgG or PBS (P < 0.001), when treatment was initiated immediately, and similar results were obtained when treatment started on day 6. Microvessel density in tumors of DC101-treated animals was reduced by at least 40% compared with animals treated with control IgG or PBS (P < 0.01). We observed a reduction in tumor cell proliferation and an increase in apoptosis in DC101-treated animals (P < 0.001). However, in mice treated with DC101, we also noticed a striking increase in the number and total area of small satellite tumors clustered around, but distinct from, the primary. These satellites usually contained central vessel cores, and tumor cells often had migrated over long distances along the host vasculature to eventually reach the surface and spread leptomeningeally. We conclude that systemic antagonization of VEGFR-2 can inhibit glioblastoma neovascularization and growth but can lead to increased cooption of preexistent cerebral blood vessels. Therefore, a combination of different treatment modalities which also include anti-invasive therapy may be needed for an effective therapy against glioblastoma, and the use of an antibody against VEGFR-2 may be one effective component.

Introduction

Over the past decades there have been only minor improvements in the prognosis for patients with glioblastomas. Because glioblastomas as well as virtually all other tumors require angiogenesis to sustain growth, and malignant gliomas have been shown to be among the most densely vascularized tumors (1), antagonization of angiogenesis might be a promising treatment strategy. VEGF3 is a crucial mediator of glioblastoma angiogenesis. It is secreted by the tumor cells and acts on the endothelial cells, which express the receptors VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1/KDR; Ref. 2). Whereas VEGFR-2 seems to mediate the major growth and permeability actions of VEGF, VEGFR-1 may act either as a decoy receptor or by suppressing signaling through VEGFR-2 (3). In malignant gliomas VEGF is preferentially expressed around necrotic (hypoxic) areas (2), and levels of VEGF protein as well as mRNA correlate with the malignancy grade and microvessel density of gliomas (4, 5).

Previously, the interaction between VEGF and its receptors has been antagonized by monoclonal antibodies, expression of a dominant-negative receptor or antisense, and by small molecules, thereby inhibiting the growth of glioma xenografts in a variety of rodent models (6–11). Recently it was described that DC101, a mAb against mouse VEGFR-2 (12), could potently inhibit the angiogenesis and growth of several different s.c. tumor xenografts, including human glioblastomas, in nude mice (6). However, when evaluating antiangiogenic strategies in animal models, one must consider that the morphology, function, and antigen expression pattern of the tumor vasculature is largely dependent upon the host environment (13, 14). Therefore, and also because gliomas in contrast to peripheral tumors tend to migrate over long distances, preferably along preexistent cerebral blood vessels, any experimental strategy directed against gliomas should best be evaluated in an orthotopic model. For this reason, we treated glioblastomas grown intracerebrally in SCID mice with DC101 and determined its effect on tumor size and vascularity as well as the proliferative activity and apoptosis in vivo.

Materials and Methods

Antibodies. The rat mAb DC101 against mouse VEGFR-2 (12) was provided by ImClone Systems, Inc. (New York, NY). Control polyclonal rat IgG was purchased from Jackson ImmunoResearch Laboratories (West Grove, PA). mAb A4.6.1 against VEGF was a kind gift of Dr. Napoleone Ferrara (Genentech, Inc., San Francisco, CA). The polyclonal antibody against vWF and the mAb MIB-1 against the Ki-67 antigen were obtained from Dako (Hamburg, Germany).

Cell Culture. G55 cells that had previously undergone one round of in vivo selection in nude mice were grown in DMEM with 10% FCS. For animal experiments, cell inoculum consisted of the desired number of cells in 5 μl of serum-free tissue culture medium supplemented with 2% methyl cellulose (Sigma Chemical Co., St. Louis, MO).

Orthotopic Glioma Model. Intracerebral G55 xenografts were established following a protocol by Dr. Yancey Gillespie (15). Female SCID mice (C.B.-17 scid/scid), 11–12 weeks of age, were anesthetized by i.p. administration of ketamine (100 mg/kg body weight) and xylazine (5 mg/kg body weight). A midline scalp incision was made, and a 0.5-mm burr hole was drilled in the skull 1.5 mm to the right of the midline and 0.5 mm anterior to the bregma. Tumor cells (7 × 10^4 cells/dose) were loaded into a 250-μl Hamilton syringe fitted with a 30-gauge 0.5-inch needle, attached to a repeating dispenser, and mounted in a stereotoxic holder (TSE Systems, Bad Homburg, Germany). The needle was inserted vertically through the burr hole to a depth of 2.5 mm. After injection of 5 μl of cells into the right caudate nucleus, the needle was withdrawn after 2 min, the burr hole was tamped with bone wax, and the skin was closed with wound clips. The first group of mice were treated i.p. with the mAb DC101 (800 μg/dose in 200 μl PBS), control rat IgG (800 μg/200 μl), or PBS only (200 μl), starting on the day of tumor cell implantation.
Inhibition of Glioma Angiogenesis

Injection, every other day over a total of 16 days. The experiment was repeated with a modified schedule, where mice received injections of DC101, control IgG, or PBS in the same doses, but treatment was initiated on day 6 of the experiment, and mice were killed on day 15 using CO2.

Determination of Tumor Size. Mouse brains were removed from the cranial cavity, bisected coronally at the injection site, embedded in OCT compound (Tissue Tek, Elkhart, IN), and stored in liquid nitrogen. Serial frozen sections (12 μm thick) were stained with H&E. The maximum cross-sectional area of the intracranial glioblastoma xenografts as well as the area of smaller satellite tumors distinct from the primary was determined by computer-assisted image analysis. The tumor volume was estimated with the formula: volume = (square root of maximal tumor cross-sectional area) 3.

Results

VEGF Expression in Vivo. For in vivo experiments we used the glioblastoma cell line G55, which secretes VEGF in vitro (not shown). Stereotactic injection of 7 × 103 G55 cells into the basal ganglia of SCID mice resulted in a 100% tumor take rate. In these tumors, VEGF expression was demonstrated by Western blot and in situ hybridization analysis (Fig. 1, A–C). Histologically, the tumors resembled human glioblastomas, displaying pseudopalisading necroses and hypervascularity.

Tumor Growth in Vivo. In the first set of experiments, treatment with DC101, control IgG, or PBS was initiated on the day of the tumor cell implantation and continued over a total of 16 days. The mean tumor volume in DC101-treated animals was reduced by 59% compared with IgG controls (2.92 ± 0.82 mm3 versus 7.16 ± 2.01 mm3, respectively; P < 0.001), and by 81% compared with PBS controls (15.41 ± 6.133 mm3; P < 0.001); notably, the size of tumors in IgG-treated mice was also reduced by 54% compared with PBS controls (P < 0.01; Fig. 1, D–F and Fig. 2A). In the repeat experiment, treatment was initiated on day 6 after tumor cell injection to investigate whether DC101 treatment was also effective against already-established tumors. From pilot experiments we knew that tumors reached a size of ~1 mm3 after 6 days and usually would have killed the animals at ~3 weeks of growth. By the end of this second experiment, the mean tumor volume in mice treated with DC101 was reduced by 72% compared with IgG controls (P = 0.001), and by 81% compared with PBS controls (P < 0.001; not shown). In contrast with the first set of experiments, tumors in the IgG control group were not significantly smaller than tumors in the PBS control group (P = 0.751).

Tumor Morphology. We observed a strikingly more invasive pattern of tumor growth in mice treated with DC101 compared with both control groups. Glioblastoma xenografts usually grow as relatively well-circumscribed masses when injected into the caudate/putamen of SCID mice (Fig. 1G); however, in DC101-treated animals, a striking increase in the number of satellite tumor that were clustered around, but distinct from, the primary was observed (Fig. 1H). These satellites usually contained discernible central vessel cores (Fig. 1I). On some sections, it became evident that the satellites represented cross sections of vessels that were surrounded over a long distance by a coat of tumor cells (Fig. 1J). Sometimes, such vessels even could be traced to the brain surface, so that, apparently, tumor cells had migrated into the Virchow-Robin space to eventually reach the meninges and spread in the subarachnoid space (Fig. 1K). Quantification of tumor satellites revealed that, in the first set of experiments, their frequency was ~5.5-fold greater in the DC101-treated animals than in either IgG- or PBS-controls (P < 0.01; Fig. 2B). The total satellite tumor area was ~4-fold greater in DC101-treated mice than in either IgG- or PBS-controls (P < 0.05 and P < 0.01, respectively; Fig. 2C). Similarly, in the second set of experiments, the number of satellites was 5-fold greater in DC101-treated mice compared with IgG-controls (P < 0.001), and 1.7-fold greater than in PBS-controls (P < 0.05; not shown). The total satellite tumor area was 4.8-fold greater in DC101-treated animals than in IgG-controls (P < 0.001).
Fig. 1. Examination of tumors in DC101-treated mice and controls. In situ hybridization of a tumor derived from cell line G55 grown intracranially in an untreated mouse revealed expression of VEGF mRNA predominantly around necrotic tumor areas (A, antisense hybridization; B, sense control; both ×40). Western blot analysis of tissue generated from an intracranially grown G55-derived tumor revealed a major band at M_r 23,000 corresponding to the major splice variant VEGF_165 (C). Representative size examples of G55-derived tumors grown intracranially in mice treated with DC101 (D), IgG (E), or PBS (F; D–F, H&E staining, ×10). Whereas tumors in control animals usually displayed well-delineated margins (G, example of an IgG-treated tumor), tumors in DC101-treated animals were usually surrounded by numerous smaller satellite tumors (H); the satellites usually contained central vessel cores (I, arrows); when cut longitudinally, the satellites could be identified as tumor cells migrating along central vessels away from the tumor mass, taking the shape of finger-like protrusions (J); occasionally, such finger-like extensions could be traced from the tumor to the cortical surface where tumors cells then spread in the subarachnoid space (K; G–K, H&E staining, ×35). Immunostaining for vWF revealed a dense capillary network in control tumors (L, IgG-control), but only sparse vascularization in tumors from DC101-treated mice (M; both ×170). The average percentage of Ki-67 immunoreactive cells was significantly higher in control tumors (N, IgG-control) than in tumors of DC101-treated animals (O; both ×375). The percentage of apoptotic cells as determined by TUNEL-staining was lower in control tumors (P, IgG-control) than in tumors from DC101-treated mice (Q; both ×225).
and 2.9-fold greater than in PBS-controls ($P < 0.003$) when treatment was initiated on day 6 (not shown). No significant differences between the mean individual satellite areas were observed between the three treatment groups, regardless of whether treatment was initiated on day 0 (Fig. 2D) or on day 6 (not shown).

**Tumor Microvessel Density.** Vessel densities were quantified on histological sections after staining for vWF, which specifically labels endothelial cells. In DC101-treated SCID mice, intratumoral microvessel density was reduced by 43 and 41% compared with IgG controls and PBS controls, respectively ($P < 0.005$; Fig. 1, L and M, and Fig. 2E). A similar result was obtained when treatment was initiated on day 6 after tumors had established; in this second set of experiments, vessel density was reduced by 50% compared with IgG controls and by 42% compared with PBS controls ($P < 0.01$; not shown). There were no differences in vessel densities between the two control groups.

**Tumor Cell Proliferation.** The numbers of mitotic figures did not differ significantly between the three treatment groups, although a slight tendency of fewer mitoses in the DC101-treated mice is suggested in Fig. 2F. Results were similar when treatment was initiated on day 6 after tumor cell implantation (not shown). To obtain a more sensitive measure of tumor cell proliferation, we determined the percentage of cells expressing the Ki-67 antigen. In this comparison, differences became more obvious with an ~25%-reduction of proliferative activity in tumors of DC101-treated mice compared with controls ($P < 0.001$; Fig. 1N and O and Fig. 2G). A similar result with an almost 25%-reduced average MIB-1 labeling-index in the DC101 group compared with both controls was obtained when treatment was initiated on day 6 ($P < 0.001$; not shown). No differences were observed between the two control groups.

Notably, DC101 had no effect on the proliferation of G55 cells over 5 days in vitro when added at concentrations ranging from 0.5 ng/ml to 5 µg/ml (not shown). Moreover, in a modified Boyden chamber assay, no effect on the random motility of G55 cells could be observed upon addition of DC101 in concentrations ranging from 0.1 ng/ml to 50 µg/ml (not shown).

**Tumor Cell Apoptosis.** DC101-treated animals displayed a >3-fold higher percentage of apoptotic tumor cells in comparison with both IgG- and PBS-controls ($P < 0.001$; Fig. 1, P and Q, and Fig. 2H). A similar result was obtained when treatment started on day 6, with an at least 3.5-fold-increased apoptotic rate in tumors of DC101-treated mice compared with both control groups ($P < 0.001$; not shown). There were no differences between the two control groups.

**Discussion**

The results of this study demonstrate that blockade of VEGFR-2 by systemic administration of DC101 inhibits angiogenesis and growth of human glioblastoma xenografts in an orthotopic model. Antibody treatment was well tolerated; we did not observe any signs of antibody toxicity, and there were no organ abnormalities at autopsy. Tumor volumes in DC101-treated animals were reduced by 59 and by 81% compared with IgG and PBS controls, respectively, when treatment was initiated immediately, and similar results were obtained when treatment started on day 6 after tumor cell implantation. Microvessel density in tumors of DC101-treated animals was reduced by at least 40% compared with animals treated with control IgG or PBS. We did not observe any significant effect of DC101 on glioblastoma cell growth or migration in vitro, suggesting that the inhibition of tumor growth in vivo is caused by the specific inhibition of tumor angiogenesis through the blockade of VEGFR-2-signaling. Furthermore, we observed a decrease in tumor-cell proliferation and an increase in apoptotic tumor cells in DC101-treated mice, which can be interpreted as a consequence of the lack of new vasculature needed to supply the rapidly growing tumor mass and may also indicate the lack of growth and survival factors produced by the tumor vasculature.
Interestingly, morphological analysis of tumor growth patterns in all experiments consistently revealed a significant increase in the number and total area of satellite tumors clustered around the main tumor mass in DC101-treated animals compared with controls. The satellites usually contained central vessel cores, and tumor cells had often migrated over long distances along these vessels to eventually reach the surface and invade the leptomeninges. Such a pattern of migration is similar to the growth pattern of gliomas in humans, which often invade the brain along the host vasculature in the Virchow-Robin space, so that tumor cell capping of vessels in some distance to the main tumor mass is a frequent neuropathological finding. Recently, it has been verified experimentally that gliomas can coopt preexistent cerebral vessels to provide their blood supply before they induce neovascularization (18). Our results suggest that in a therapeutically pertinent situation where angiogenesis is inhibited, the two pathways can become alternatives, so that blockade of neovascularization favors vessel cooption. Interestingly, a similar result was obtained using an alternative approach with an antibody against VEGF, where treatment resulted in increased survival in glioblastoma-bearing nude mice compared with PBS controls, but also led to increased invasiveness along host vessels (8). These findings demonstrate that it is essential to evaluate antiangiogenic therapies in orthotopic models, because angiogenic mechanisms may differ greatly between different organs and tumor types.

Another important finding of our study is that systemic application of DC101 was effective against an intracerebral tumor. A recent study showed that an mAb against a tumor-specific mutant variant of the epidermal growth factor receptor was only effective when applied locally into intracerebral tumors, but not systemically (19). The advantage of DC101 in this comparison is that it only needs to reach the abluminal side of the endothelial cells where VEGFR-2 is mainly located (20), but not to fully cross the blood-brain barrier and diffuse through the brain parenchyma. Interestingly in this context, we also observed an effect of cIgG, though by far not as great as that of DC101.

A recent study showed that human IgG when injected i.v. into SCID mice reduced the formation of melanoma metastases, and the effect was mainly attributed to an enhancement of natural killer cell activity and interleukin-12 production by mononuclear cells (21), which explains its systemic effect also in our study. The fact that IgG only had a significant effect when treatment was initiated immediately could mean that either IgG is less effective against already established tumors, or that its effect requires more time. It is relatively common to use polyclonal IgG from the same species as the antibody to be tested as a control (6, 22); alternatively, in many studies just saline is used as a control (6, 22); alternatively, in many studies just saline is used as a control (6, 22). It is particularly important to use polyclonal IgG as a control, effects of any antibody to be tested could be masked to some extent in this comparison.

In summary, we have shown that systemic treatment with an antibody against VEGFR-2 inhibits glioblastoma angiogenesis in vivo and leads to a decrease in tumor volume, but at the same time causes an increase in tumor invasiveness along host microvasculature. These findings suggest that a combination of different treatment regimes which also include anti-invasive therapy may be needed for an effective therapy against glioblastoma, and the use of an antibody against VEGFR-2 may be one effective component.

Acknowledgments

We are indebted to Dr. Yancey Gillespie for his advice regarding the establishment of the brain tumor model. We thank Drs. Jens Dimigen and Franz Iglauser as well as Roswitha Reusch for their support with the animal experiments. We are grateful to Dr. Napoleon Ferrara for providing the antibody A4.6.1 and to Dr. Karl Plate for providing the VEGF probe.

References